Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders
- 4 August 2011
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 27 (9) , 1815-1826
Abstract
Objective:This post hoc analysis examined efficacy and tolerability of open-label desvenlafaxine in patients with major depressive disorder switched from blinded placebo, venlafaxine extend...Keywords
This publication has 34 references indexed in Scilit:
- A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorderInternational Clinical Psychopharmacology, 2008
- Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorderCurrent Medical Research and Opinion, 2008
- Switching to Duloxetine From Selective Serotonin Reuptake Inhibitor AntidepressantsThe Journal of Clinical Psychiatry, 2008
- Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake InhibitorThe Journal of Pharmacology and Experimental Therapeutics, 2006
- An Open-label Study of Duloxetine for the Treatment of Major Depressive DisorderJournal of Clinical Psychopharmacology, 2005
- Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetineClinical Therapeutics, 2004
- The Economic Burden of Depression in the United StatesThe Journal of Clinical Psychiatry, 2003
- Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxineDrug Development Research, 1991
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960